Syndax Pharmaceuticals' Series C Round

Syndax Pharmaceuticals raised a round of funding on August 24, 2015.

Syndax is a clinical stage biopharmaceutical company developing entinostat as a combination therapy in multiple cancer indications with an initial focus on tumors that have shown sensitivity to immuno…

Articles about Syndax Pharmaceuticals' Series C Round: